Panorama regulatorio de las vacunas personalizadas en cáncer en Colombia: perspectivas y futuro (insumo para policy brief)

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492

Copier J, Bodman-Smith M, Dalgleish A. Current status and future applications of cellular therapies for cancer. Immunotherapy. 2011;3(4):507-16. https://doi.org/10.2217/imt.11.18

Waldman A, Fritz J, Lenardo M. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651-68. https://doi.org/10.1038/s41577-020-0306-5

Pento J. Monoclonal antibodies for the treatment of cancer. Anticancer Res. 2017;37(11):5935-9. https://doi.org/10.21873/anticanres.12040

Kimiz-Gebologlu I, Gulce-Iz S, Biray-Avci C. Monoclonal antibodies in cancer immunotherapy. Mol Biol Rep. 2018;45(6):2935-40. https://doi.org/10.1007/s11033-018-4427-x

Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. Science. 2018;359(6382):1355-60. https://doi.org/10.1126/science.aar7112

Esfahani K, Roudaia L, Buhlaiga N, Del Rincon S, Papneja N, Miller W. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol. 2020;27(supl. 2):S87-97. https://doi.org/10.3747/co.27.5223

Guo C, Manjili M, Subjeck J, Sarkar D, Fisher P, Wang X. Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res. 2013;119:421-75. https://doi.org/10.1016/b978-0-12-407190-2.00007-1

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20(1):7-24. https://doi.org/10.1038/s41577-019-0210-z

Ortiz-Aguirre J, Velandia-Vargas E, Rodríguez-Bohorquez O, Amaya-Ramírez D, Bernal-Estévez D, Parra-López C. Personalized neoantigen-based cancer immunotherapy: a literature review. Rev Fac Med. 2021;69(3):117-31. https://doi.org/10.15446/revfacmed.v69n3.81633

Schumacher T, Schreiber R. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69-74. https://doi.org/10.1126/science.aaa4971

Peipins L, Soman A, Berkowitz Z, White M. The lack of paid sick leave as a barrier to cancer screening and medical care-seeking: results from the National Health Interview Survey. BMC Public Health. 2012;12:520. https://doi.org/10.1186/1471-2458-12-520

European Commission. Guidelines on good clinical practice specific to advanced therapy medicinal products [internet]. Bruselas: European Commission; 2019. [citado 2025 sept. 22]. Disponible en: https://health.ec.europa.eu/document/download/2d8842cb-e785-488f-bfd0-bf8f2dab1efe_en

Heelan B. Regulatory considerations for clinical development of cancer vaccines. Hum Vaccin Immunother. 2014;10(11):3409-14. https://doi.org/10.4161/21645515.2014.982999

European Medicines Agency. Evaluation of anticancer medicinal products - Scientific guideline [internet]. European Medicines Agency. [citado 2025 sept. 22]. Disponible en: https://www.ema.europa.eu/en/evaluation-anticancer-medicinal-products-scientific-guideline

Center for Biologics Evaluation and Research. Guidance for industry: clinical considerations for therapeutic cancer vaccines [internet]. Estados Unidos: Food and Drug Administration; 2011. [citado 2025 sept. 22] Disponible en: https://www.fda.gov/files/vaccines,%20blood%20&%20biologics/published/Guidance-for-Industry--Clinical-Considerations-for-Therapeutic-Cancer-Vaccines.pdf

European Medicines Agency. Guideline on the evaluation of anticancer medicinal products in man [internet]. Londres: European Medicines Agency; 2017. [citado 2025 sept. 22]. Disponible en: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-anticancer-medicinal-products-man-revision-5_en.pdf

Ministerio de Salud y Protección Social. ABECÉ sobre medicamentos biotecnológicos [internet]. Colombia: MinSalud; 2014. [citado 2025 sept. 22]. https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/MET/abc-biomedicamentos.pdf

Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, et al. Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunology. 2013;2(1):e22789. https://doi.org/10.4161/onci.22789

Ferrara N, Hillan K, Gerber H, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391-400. https://doi.org/10.1038/nrd1381.

Coulie P, Van den Eynde B, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014;14(2):135-46. https://doi.org/10.1038/nrc3670.

Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, et al. Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology. 2013;2(6):e24612. https://doi.org/10.4161/onci.24612

Blalock L, Landsberg J, Messmer M, Shi J, Pardee A, Haskell R, et al. Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. Oncoimmunology. 2012;1(3):287-357. https://doi.org/10.4161/onci.18628

Kandalaft L, Powell D, Chiang C, Tanyi J, Kim S, Bosch M, et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology. 2013;2(1):e22664. https://doi.org/10.4161/onci.22664

García-Martínez E, Smith M, Buqué A, Aranda F, Ayala de la Peña F, Ivars A, et al. Trial watch: immunostimulation with recombinant cytokines for cancer therapy. Oncoimmunology. 2018;7(6):e1433982. https://doi.org/10.1080/2162402x.2018.1433982

Kaushik I, Ramachandran S, Zabel C, Gaikwad S, Srivastava S. The evolutionary legacy of immune checkpoint inhibitors. Semin Cancer Biol. 2022;86(pt. 2):491-8. https://doi.org/10.1016/j.semcancer.2022.03.020

Houot R, Kohrt H, Levy R. Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody. Oncoimmunology. 2012;1(6):957-8. https://doi.org/10.4161/onci.19974

Shevach E, Stephens G. The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity? Nat Rev Immunol. 2006;6(8):613-8. https://doi.org/10.1038/nri1867

Pickup M, Novitskiy S, Moses H. The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer. 2013;13(11):788-99. https://doi.org/10.1038/nrc3603

Favre D, Mold J, Hunt P, Kanwar B, Loke P, Seu L, et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med. 2010;2(32):32ra6. https://doi.org/10.1126/scitranslmed.3000632

Paavonen J, Naud P, Salmerón J, Wheeler C, Chow S, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301-14. https://doi.org/10.1016/s0140-6736(09)61248-4

Demaria S, Vanpouille-Box C, Formenti S, Adams S. The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer. Oncoimmunology. 2013;2(10):e25997. https://doi.org/10.4161/onci.25997

Murad Y, Clay T, Lyerly H, Morse M. CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert Opin Biol Ther. 2007;7(8):1257-66. https://doi.org/10.1517/14712598.7.8.1257

Alexopoulou L, Holt A, Medzhitov R, Flavell R. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857):732-8. https://doi.org/10.1038/35099560

Ming C, Stephenson R, Salazar A, Ferris R. TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR+ head and neck cancer cells. Oncoimmunology. 2013;2(6):e24677. https://doi.org/10.4161/onci.24677

Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51-72. https://doi.org/10.1146/annurev-immunol-032712-100008

Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29(4):482-91. https://doi.org/10.1038/onc.2009.356

Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 2011;71(3):768-78. https://doi.org/10.1158/0008-5472.can-10-2788

Hasumi K, Aoki Y, Wantanabe R, Mann D. Clinical response of advanced cancer patients to cellular immunotherapy and intensity-modulated radiation therapy. Oncoimmunology. 2013;2(10):e26381. https://doi.org/10.4161/onci.26381

Galluzzi L, Kepp O, Kroemer G. Enlightening the impact of immunogenic cell death in photodynamic cancer therapy. EMBO J. 2012;31(5):1055-7. https://doi.org/10.1038/emboj.2012.2

Spisek R, Charalambous A, Mazumder A, Vesole D, Jagannath S, Dhodapkar M. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood. 2007;109(11):4839-45. https://doi.org/10.1182/blood-2006-10-054221

Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014;11(9):509-24. https://doi.org/10.1038/nrclinonc.2014.111

Kenter G, Welters M, Valentijn A, Lowik M, Berends-van der Meer D, Vloon A, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361(19):1838-47. https://doi.org/10.1056/nejmoa0810097

Shariati A, Khezrpour A, Shariati F, Afkhami H, Yarahmadi A, Alavimanesh S, et al. DNA vaccines as promising immuno-therapeutics against cancer: a new insight. Front Immunol. 2025;15:1498431. https://doi.org/10.3389/fimmu.2024.1498431

Lorentzen C, Haanen J, Met Ö, Svane I. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 2022;23(10):e450-8. https://doi.org/10.1016/s1470-2045(22)00372-2

Blass E, Ott P. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18(4):215-29. https://doi.org/10.1038/s41571-020-00460-2

Wu D, Jia S, Xing S, Ma H, Wang X, Tang Q, et al. Personalized neoantigen cancer vaccines: current progression, challenges and a bright future. Clin Exp Med. 2024;24(1):229. https://doi.org/10.1007/s10238-024-01436-7

Hu Z, Leet D, Allesøe R, Oliveira G, Li S, Luoma A, et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med. 2021;27(3):515-25. https://doi.org/10.1038/s41591-020-01206-4

Zhang X, Goedegebuure S, Chen M, Mishra R, Zhang F, Yu Y, et al. Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients. Genome Med. 2024;16(1):131. https://doi.org/10.1186/s13073-024-01388-3

Selmi A, Vascotto F, Kautz-Neu K, Türeci Ö, Sahin U, von Stebut E, et al. Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice. Cancer Immunol Immunother. 2016;65(9):1075-83. https://doi.org/10.1007/s00262-016-1869-7

Li J, Xiao Z, Wang D, Jia L, Nie S, Zeng X, et al. The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells. Mol Cancer. 2023;22(1):141. https://doi.org/10.1186/s12943-023-01844-5

Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Hervé W, et al. Trial Watch: adoptive cell transfer for anticancer immunotherapy. Oncoimmunology. 2014;3(5):e28344. https://doi.org/10.4161/onci.28344

Jenq R, van den Brink M. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer. 2010;10(3):213-21. https://doi.org/10.1038/nrc2804

Bao C, Gao Q, Li L, Han L, Zhang B, Ding Y, et al. The application of nanobody in CAR-T therapy. Biomolecules. 2021;11(2):238. https://doi.org/10.3390/biom11020238

Ahmad A. CAR-T cell therapy. Int J Mol Sci. 2020;21(12):4303. https://doi.org/10.3390/ijms21124303

Sun D, Shi X, Li S, Wang X, Yang X, Wan M. CAR‑T cell therapy: a breakthrough in traditional cancer treatment strategies (review). Mol Med Rep. 2024;29(3):47. https://doi.org/10.3892/mmr.2024.13171

Luo W, Song D, He Y, Song J, Ding Y. Tumor vaccines for malignant melanoma: progress, challenges, and future directions. Oncol Res. 2025;33(8):1875-93. https://doi.org/10.32604/or.2025.063843

Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley D, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012;7(3):562-78. https://doi.org/10.1038/nprot.2012.016

Jørgensen K, Rasmussen M, Buus S, Nielsen M. NetMHCstab - predicting stability of peptide-MHC-I complexes; impacts for cytotoxic T lymphocyte epitope discovery. Immunology. 2014;141(1):18-26. https://doi.org/10.1111/imm.12160

Karosiene E, Lundegaard C, Lund O, Nielsen M. NetMHCcons: a consensus method for the major histocompatibility complex class I predictions. Immunogenetics. 2012;64(3):177-86. https://doi.org/10.1007/s00251-011-0579-8

Nielsen M, Lundegaard C, Lund O, Keşmir C. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics. 2005;57(1-2):33-41. https://doi.org/10.1007/s00251-005-0781-7

Pabinger S, Dander A, Fischer M, Snajder R, Sperk M, Efremova M, et al. A survey of tools for variant analysis of next-generation genome sequencing data. Brief Bioinform. 2014;15(2):256-78. https://doi.org/10.1093/bib/bbs086

Ministerio de Salud. Anmat [internet]. Argentina: Ministerio de Salud. [citado 2025 sept. 23]. Disponible en: https://www.argentina.gob.ar/anmat

Ministerio da Saúde. Agência Nacional de Vigilância Sanitária – Anvisa [internet]. Brasil: Ministerio da Saúde. [citado 2025 sept. 23]. Disponible en: https://www.gov.br/anvisa/pt-br

Ministerio de Salud Pública. Regulación n.° 27-2000. Requerimientos para ensayos clínicos fase I y II con productos en investigacion destinados al tratamiento de cancer y sida [internet]. Cuba: Ministerio de Salud Pública; 2000. [citado 2025 sept. 23]. Disponible en: http://files.sld.cu/eticaeninvestigacion/files/2022/12/Regulaci%C3%B3n-27-2000-Requerimientos-para-ensayos-cl%C3%ADnicos-Fase-I-y-II-con-productos-en-investigaci%C3%B3n-destinados-al-tratamiento-de-c%C3%A1ncer-y-sida.pdf

European Medicines Agency. Guideline on the clinical evaluation of anticancer medicinal products [internet]. Amsterdam: EMA; 2019. [citado 2025 sept. 23]. Disponible en: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-evaluation-anticancer-medicinal-products-man-revision-6_en.pdf

Invima. Medicamentos y productos biológicos [internet]. Colombia: Invima. [citado 2025 sept. 23]. Disponible en: https://invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos

Cecmed. Resolución CECMED n.° 38/2000 [internet]. Cuba: Cecmed; 2000. [citado 2025 sept. 24]. Disponible en: https://www.cecmed.cu/reglamentacion/aprobadas/resolucion-cecmed-no-382000

Cecmed. Resolución CECMED n.° 59/2010 [internet]. Cuba: Cecmed; 2010. [citado 2025 sept. 24]. Disponible en: https://www.cecmed.cu/reglamentacion/aprobadas/resolucion-cecmed-no-592010

Administración Nacional de Medicamentos, Alimentos y Técnica Médica. Disposición 179/2018 [internet]. Argentina: Administración Nacional de Medicamentos, Alimentos y Tecnología Médica; 2018. [citado 2025 sept. 24]. Disponible en: https://www.argentina.gob.ar/normativa/nacional/disposici%C3%B3n-179-2018-314546.

Poder Ejecutivo Nacional. Decreto 605/2023. Ley de Trasplante de Órganos, Tejidos y Células [internet]. Argentina: Ministerio de Justicia; 2019. [citado 2025 sept. 24]. Disponible en: https://www.argentina.gob.ar/normativa/nacional/decreto-605-2023-393618/texto

Anvisa. Relatório de análise de impacto regulatório sobre registro de produtos de terapias avançadas no Brasil [internet]. Brasil: Anvisa; 2016. [citado 2025 sept. 24]. Disponible en: https://www.gov.br/anvisa/pt-br/assuntos/regulamentacao/air/analises-de-impacto-regulatorio/2019/25351-494647_2015-91-relatorio-de-air-sobre-registro-de-produtos-de-terapias-avancadas-no-brasil.pdf

Presidência da República. Lei n.° 9.434, de 04 de fevereiro de 1997, dispõe sobre a remoção de órgãos, tecidos e partes do corpo humano para fins de transplante e tratamento e dá outras providências [internet]. Brasil: Presidência da República; 1997. [citado 2025 sept. 24]. Disponible en: https://www.planalto.gov.br/ccivil_03/leis/l9434.htm

Presidência da República. Lei n.° 11.105, de 24 de março de 2005, regulamenta os incisos II, IV e V do § 1º do art. 225 da Constituição Federal, estabelece normas de segurança e mecanismos de fiscalização de atividades que envolvam organismos geneticamente modificados – OGM e seus derivados, cria o Conselho Nacional de Biossegurança – CNBS, reestrutura a Comissão Técnica Nacional de Biossegurança – CTNBio, dispõe sobre a Política Nacional de Biossegurança – PNB, revoga a Lei n.° 8.974, de 5 de janeiro de 1995, e a Medida Provisória n.° 2.191-9, de 23 de agosto de 2001, e os arts. 5º , 6º , 7º , 8º , 9º , 10 e 16 da Lei n.° 10.814, de 15 de dezembro de 2003, e dá outras providências [internet]. Brasil: Presidência da República; 2005. [citado 2025 sept. 24]. Disponible en: https://www.planalto.gov.br/ccivil_03/_ato2004-2006/2005/lei/l11105.htm

Anvisa. Resolução da Colegiada - RDC n.° 338, de 20 de fevereiro de 2020, dispõe sobre o registro de produto de terapia avançada e dá outras providências [internet]. Brasil: Ministério da Saúde; 2020. [citado 2025 sept. 24]. Disponible en: https://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2020/RDC_338_2020_.pdf

Cecmed. Resolución CECMED n.° 94/2016 [internet]. Cuba: Cecmed; 2016. [citado 2025 sept. 24]. Disponible en: https://www.cecmed.cu/content/00-270

Unión Europea. Directiva 2001/83/CE del Parlamento Europeo y del Consejo, de 6 de noviembre de 2001, por la que se establece un código comunitario sobre medicamentos para uso humano [internet]. Unión Europea; 2001. [citado 2025 sept. 24]. Disponible en: https://www.boe.es/buscar/doc.php?id=DOUE-L-2001-82523

European Union. Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 [internet]. European Union; 2007. [citado 2025 sept. 24]. Disponible en: https://eur-lex.europa.eu/eli/reg/2007/1394/oj/eng

U.S. Food and Drug Administration (FDA). Vaccines, Blood & Biologics [internet]. Estados Unidos: FDA. [citado 2025 sept. 24]. Disponible en: https://www.fda.gov/vaccines-blood-biologics

Vatsan R, Bross P, Liu K, Theoret M, De Claro A, Lu J, et al. Regulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluation. J Immunother Cancer. 2013;1(1):5. https://doi.org/10.1186/2051-1426-1-5

Presidência da República. Decreto n.° 9.175, de 18 de outubro de 2017, regulamenta a Lei n.° 9.434, de 4 de fevereiro de 1997, para tratar da disposição de órgãos, tecidos, células e partes do corpo humano para fins de transplante e tratamento [internet]. Brasil: Presidência da República; 2017. [citado 2025 sept. 24]. Disponible en: https://www.planalto.gov.br/ccivil_03/_ato2015-2018/2017/decreto/d9175.htm

Unión Europea. Directiva 2002/98/CE del Parlamento Europeo y del Consejo, de 27 de enero de 2003, por la que se establecen normas de calidad y de seguridad para la extracción, verificación, tratamiento, almacenamiento y distribución de sangre humana y sus componentes y por la que se modifica la Directiva 2001/83/CE [internet]. European Union; 2003. [citado 2025 sept. 24]. Disponible en: https://eur-lex.europa.eu/legal-content/ES/ALL/?uri=CELEX:32002L0098

Center for Biologics Evaluation and Research. Eligibility determination for donors of human cells, tissues, and cellular and tissue-based products [internet]. Estados Unidos: Food and Drug Administration; 2007. [citado 2025 sept. 24]. Disponible en: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/eligibility-determination-donors-human-cells-tissues-and-cellular-and-tissue-based-products

U.S. Food and Drug Administration. CFR - Code of Federal Regulations title 21 [internet]. Estados Unidos: Food and Drug Administration; 2024. [citado 2025 sept. 24]. Disponible en: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm

Ministerio de Protección Social. Decreto 2493 de 2004, por el cual se reglamentan parcialmente las Leyes 9ª de 1979 y 73 de 1988, en relación con los componentes anatómicos [internet]. Diario oficial 45631; 2004. [citado 2025 sept. 24]. Disponible en: https://www.alcaldiabogota.gov.co/sisjur/normas/Norma1.jsp?i=14525

Ministerio de la Protección Social. Resolución 5108 de 2005, por la cual se establece el Manual de Buenas Prácticas para Bancos de Tejidos y de Médula Osea y se dictan otras disposiciones [internet]. Diario oficial 46154; 2006. [citado 2025 sept. 24]. Disponible en: https://minsalud.gov.co/Normatividad_Nuevo/RESOLUCI%C3%93N%205108%20DE%202005.pdf

Hsu C-H, Cheng A-L. Clinical studies with curcumin. En: Aggarwal B, Surh Y, Shishodia S, editores. Advances in Experimental Medicine and Biololgy. Boston: Springer; 2007. p. 471-80. https://doi.org/10.1007/978-0-387-46401-5_21

European Medicines Agency. Committee for Advanced Therapies (CAT) [internet]. EMA. [citado 2025 sept. 24]. Disponible en: https://www.ema.europa.eu/en/committees/committee-advanced-therapies-cat

Union Europea. Directiva 2004/23/CE del Parlamento Europeo y del Consejo, de 31 de marzo de 2004, relativa al establecimiento de normas de calidad y de seguridad para la donación, la obtención, la evaluación, el procesamiento, la preservación, el almacenamiento y la distribución de células y tejidos humanos [internet]. European Union; 2004. [citado 2025 sept. 24]. Disponible en: https://eur-lex.europa.eu/legal-content/ES/ALL/?uri=celex:32004L0023

Center for Biologics Evaluation and Research. Content and Review of Chemistry, Manufacturing, and Control (CMC) information for human somatic cell therapy Investigational New Drug Applications (INDs) [internet]. Estados Unidos: Food and Drug Administration; 2008. [citado 2025 sept. 24]. Disponible en: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-and-review-chemistry-manufacturing-and-control-cmc-information-human-somatic-cell-therapy

EU Commission. Guidelines on good manufacturing practice specific to advanced therapy medicinal products [internet]. EU Commission; 2017. [citado 2025 sept. 24]. Disponible en: https://www.gmp-compliance.org/guidelines/gmp-guideline/guidelines-on-good-manufacturing-practice-specific-to-advanced-therapy-medicinal-products

Center for Biologics Evaluation and Research. Guidance for industry: guidance for human somatic cell therapy and gene therapy [internet]. Estados Unidos: Food and Drug Administration; 1998. [citado 2025 sept. 24]. Disponible en: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-human-somatic-cell-therapy-and-gene-therapy

Congreso de Colombia. Resolución 1480 de 2011, por medio de la cual se expide el Estatuto del Consumidor y se dictan otras disposiciones [internet]. Diario oficial 48220; 2011. [citado 2025 sept. 24]. Disponible en: https://www.funcionpublica.gov.co/eva/gestornormativo/norma.php?i=44306.

Ministerio de Salud. Resolución 8430 de 1993, por la cual se establecen las normas científicas, técnicas y administrativas para la investigación en salud [internet]. Colombia: Ministerio de Salud; 1993. [citado 2025 sept. 24]. Disponible en: https://normograma.invima.gov.co/compilacion/docs/resolucion_minsalud_r8430_93.htm

Ministerio de la Protección Social. Resolución 2378 de 2008, por la cual se adoptan las Buenas Prácticas Clínicas para las instituciones que conducen investigación con medicamentos en seres humanos [internet]. Diario Oficial 47033; 2008. [citado 2025 sept. 25]. Disponible en: https://www.ins.gov.co/Normatividad/Resoluciones/RESOLUCION%202378%20DE%202008.pdf

Ott P, Hu Z, Keskin D, Shukla S, Sun J, Bozym D, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217-21. https://doi.org/10.1038/nature22991

Rojas L, Sethna Z, Soares K, Olcese C, Pang N, Patterson E, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144-50. https://doi.org/10.1038/s41586-023-06063-y

Weber J, Carlino M, Khattak A, Meniawy T, Ansstas G, Taylor M, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403(10427):632-44. https://doi.org/10.1016/s0140-6736(23)02268-7

Ministerio de Salud y Protección Social. Decreto 1782 de 2014, por el cual se establecen los requisitos y el procedimiento para las Evaluaciones Farmacológica y Farmacéutica de los medicamentos biológicos en el trámite del registro sanitario [internet]. Diario oficial 49278; 2014. [citado 2025 sept. 24]. Disponible en: https://www.funcionpublica.gov.co/eva/gestornormativo/norma.php?i=59505

Ponomarev A, Shubina I, Sokolova Z, Baryshnikova M, Kosorukov V. Transplantable murine tumors in the studies of peptide antitumor vaccines. Oncol Rev. 2024;17:12189. https://doi.org/10.3389/or.2023.12189

Chandran S, Ma J, Klatt M, Dündar F, Bandlamudi C, Razavi P, et al. Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nat Med. 2022;28(5):946-57. https://doi.org/10.1038/s41591-022-01786-3

Bernal-Estévez D, Ortíz M, Ortíz-Montero P, Cifuentes C, Sánchez R, Parra-López C. Autologous dendritic cells in combination with chemotherapy restore responsiveness of T cells in breast cancer patients: a single-arm phase I/II trial. Front Immunol. 2021;12:669965. https://doi.org/10.3389/fimmu.2021.669965

Congreso de la República de Colombia. Ley 1438 de 2011, por medio de la cual se reforma el Sistema General de Seguridad Social en Salud y se dictan otras disposiciones [internet]. Diario oficial 47957; 2011. [citado 2025 sept. 25]. Disponible en: https://www.funcionpublica.gov.co/eva/gestornormativo/norma.php?i=41355

Ministerio de Salud y Protección Social. Resolución 3619 de 2013, por la cual se expide el Manual de Buenas Prácticas de Laboratorio de Control de Calidad de Productos Farmacéuticos, se establece la guía de evaluación y se dictan otras disposiciones [internet]. Diario oficial 49918; 2013. [citado 2025 sept. 24]. Disponible en: https://www.minsalud.gov.co/Normatividad_Nuevo/Resoluci%C3%B3n%203619%20de%202013.pdf.

Ministerio de Salud y Protección Social. Resolución 1160 de 2016, por la cual se establecen los Manuales de Buenas Prácticas de Manufactura y las Guías de Inspección de Laboratorios o Establecimientos de Producción de medicamentos, para la obtención del Certificado de Cumplimiento de las Buenas Prácticas de Manufactura [internet]. Diario oficial 49840; 2016. [citado 2025 sept. 24]. Disponible en: https://www.minsalud.gov.co/Normatividad_Nuevo/Resoluci%C3%B3n%201160%20de%202016.pdf

Ministerio de Salud. Decreto 677 de 1995, por el cual se reglamenta parcialmente el Régimen de Registros y Licencias, el Control de Calidad, así como el Régimen de Vigilancia Sanitaria de Medicamentos, Cosméticos, Preparaciones Farmacéuticas a base de Recursos Naturales, Productos de Aseo, Higiene y Limpieza y otros productos de uso doméstico y se dictan otras disposiciones sobre la materia [internet]. Diario oficial 41827; 1995. [citado 2025 sept. 25]. Disponible en: https://www.alcaldiabogota.gov.co/sisjur/normas/Norma1.jsp?i=9751

Ministerio de Salud y Protección Social. Decreto 2078 de 2012, por el cual se establece la estructura del Instituto Nacional de Vigilancia de Medicamentos y Alimentos (Invima), y se determinan las funciones de sus dependencias [internet]. Diario oficial 48577; 2012. [citado 2025 sept. 25]. Disponible en: https://www.funcionpublica.gov.co/eva/gestornormativo/norma.php?i=66709

US Federal Register. 21 CFR Part 1271 Human Cells, Tissues, And Cellular and Tissue-Based Products [internet]. Washington, DC: U.S. Government Publishing Office / eCFRv; 2025. [citado 2025 sept. 25]. Disponible en: https://www.gmp-compliance.org/guidelines/gmp-guideline/21-cfr-part-1271-human-cells-tissues-and-cellular-and-tissue-based-products

World Health Organization. TRS 1019 - 53rd report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations [internet]. Ginebra, Suiza: World Health Organization; 2019. [citado 2025 sept. 25]. Disponible en: https://www.who.int/publications/i/item/WHO_TRS_1019

Martinez L, Bernal-Estévez D, Alzate-Gutierrez D, Amaya-Ramirez D, Reyes-Cortés O, Parra-Lopez C. Personalized medicine in triple-negative breast cancer: combining neoantigen vaccination and genomic profiling in a patient undergoing neoadjuvant chemotherapy. Front Oncol. 2025;15:1623402. https://doi.org/10.3389/fonc.2025.1623402